Peptide News Digest

#Ct388-103

2 stories

Clinical Trials · View digest

Roche Enicepatide CT388-103 Phase 2 at ADA: 22.5% Placebo-Adjusted Weight Loss at 48 Weeks, 40% Reaching 25% Loss

Genentech presented Phase 2 CT388-103 data for enicepatide, the once-weekly GLP-1/GIP dual agonist, at the Roche investor event Monday June 8. The 48-week study produced 22.5% placebo-adjusted weight loss in adults with overweight or obesity, with 26% of participants losing more than 30% of body weight and almost 40% reaching at least 25%. Both enicepatide and petrelintide advance into Phase 3, and the planned Phase 2 multi-arm fixed-dose combination of the two starts mid-2026.

Industry · View digest

Genentech Queues Petrelintide ZUPREME-1 and Enicepatide CT388-103 for Monday Investor Event at ADA 2026

Genentech, Roche's US arm, will present detailed Phase 2 ZUPREME-1 data for the amylin analog petrelintide and Phase 2 CT388-103 data for the GLP-1/GIP agonist enicepatide as late-breakers at ADA 2026, with a June 8 virtual investor event. The Roche obesity package combines the two peptides as a planned fixed-dose Phase 2 combination later this year, and the company has projected $9 billion in peak annual sales for the combined pipeline.